A study of a new long-acting shot to prevent HIV
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be HIV-negative (confirmed by a test).
- You must have had anal sex without a condom in the last year (not only with a long-term partner).
- You must have had at least one of these in the last 6 months: 2 or more anal-sex partners within 3 months, a recent STD (gonorrhea, chlamydia, or syphilis), or used stimulant drugs like meth or cocaine with sex in the last 3 months.
- You cannot have a current or long-term hepatitis B infection.
- You cannot have taken any long-acting HIV prevention shot (like cabotegravir or lenacapavir) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.